Updated: Boston Scientific Buys Axonics For $3.4BN; Adds Neuromodulation To Incontinence Lineup
Executive Summary
Analysts support Boston Scientific's plan to buy Axonics for $3.4bn in cash. The deal is expensive, but gives Boston Scientific a strong position in the fast-growing sacral neuromodulation (SNM) therapy market and boosts its existing portfolio of products for incontinence.